Royalty Pharma plc (RPRX)

NASDAQ: RPRX · USD

$64.8

-0.48 (-0.7%)· Recorded snapshot

Market cap	37.3B
Revenue (ttm)	2.5B
Net income (ttm)	812M
EPS (ttm)	$1.86
Shares out	575M
P/E (trailing)	34.8x
P/E (forward)	11.8x
Dividend	$0.94 (1.46%)
Volume	1,942,518
Beta	0.41

Market data

Price

Recent price action with selectable time range.

Financial snapshot

Revenue (ttm): 2.5B
Net income (ttm): 812M
EPS (ttm): $1.86
P/E (trailing): 34.8x
P/E (forward): 11.8x
Market cap: 37.3B

Ticker	Name	Market cap	P/E	P/S	ROIC	5Y rev CAGR	1Y total return	Rating
EXAS	Exact Sciences Corp	—	—	—	—	—	—	Mantener

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector percentile context

Refreshed 2026-10-28 19:55 UTC

Forward P/E11.8

P25 13.4P50 20.2P75 35.7

Trailing P/E34.8

P25 15.4P50 25.8P75 43.5

ROE14

P25 -113.8P50 -46.5P75 -0.9

ROIC5.3

P25 -68.5P50 -27.1P75 1.8

Benchmarks · 1M

All RPRX indicators

Market & fundamental data

Available fields

264

Groups with data

Currency

USD

Showing 264 of 264 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Amount currency	USD
CIK code	0001802768
Company name	Royalty Pharma plc
Country	United States
Country code	US
CUSIP number	G7709Q104
Earnings date	2026-11-04
Earnings time	bmo
Employees	100
Employees change	1
Employees growth	1.01%
Enterprise value	$45.4B
Exchange	NASDAQ
Financial currency	USD
Financial report date	2026-06-30
First seen	2026-05-09
Fiscal year end	December
Founded	1996
Industry	Biotechnology
IPO date	2020-06-16
Is primary listing	Yes
Is SPAC	No
ISIN number	GB00BMVP7Y09
Last 10-K release date	2026-02-11
Last earnings date	2026-08-05
Last refreshed	2026-10-28
Last stock split type	Never
Market cap	$37.3B
Market cap category	Large-Cap
Next earnings date	2026-11-04
Options	Yes
Price	$64.80
Price currency	USD
Sector	Healthcare
SIC code	2834
Stock price date	2026-10-28
Symbol	RPRX
U.S. state	New York
Website	https://www.royaltypharma.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Adjusted P/E ratio	12.33x
Average P/E ratio (10Y)	41.07x
Average P/E ratio (3Y)	21.66x
Average P/E ratio (5Y)	45.92x
Earnings yield	2.88%
EV/Earnings	55.89x
EV/EBIT	29.23x
EV/EBITDA	29.14x
EV/FCF	15.25x
EV/Sales	17.9x
FCF / EV yield	6.56%
FCF yield	7.99%
Forward EV/Sales	12.47x
Forward P/E	11.84x
Forward P/S	10.24x
Graham number	25.35746
Graham upside	-60.87%
Lynch fair value	$9.32
Lynch upside	-85.61%
P/(FCF - SBC) ratio	14.62x
P/(OCF - SBC) ratio	14.62x
P/B ratio	4.26x
P/E ratio	34.76x
P/FCF ratio	12.52x
P/OCF ratio	12.52x
P/S ratio	14.69x
PEG ratio	1.59x
Price / tangible book value	6.31x
Price/EBITDA ratio	23.92x
Sector forward P/E	23.56x
Sector P/E	50.08x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
EBIT margin	61.22%
EBITDA margin	61.41%
FCF margin	117.37%
Gross margin	95.82%
Operating margin	61.22%
Pretax margin	53.11%
Profit margin	32.02%
Profit per employee	$8.1M
Profitable quarters	14
Profitable years	9
Revenue per employee	$25.4M
ROA	5.09%
ROA (5Y)	4.83%
ROCE	8.09%
ROE	13.97%
ROE (5Y)	11.64%
ROIC	5.35%
SBC / revenue	16.86%

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
EPS growth	-19.98%
EPS growth (Q)	-46.27%
EPS growth (QoQ)	-94.06%
EPS growth 3Y	48.12%
EPS growth 5Y	-5.49%
EPS growth years	0
Gross profit growth	-10%
Gross profit growth (Q)	-48.13%
Gross profit growth 3Y	20.54%
Gross profit growth 5Y	3.02%
Net income growth	-20.68%
Net income growth (Q)	-44.42%
Net income growth (QoQ)	-93.93%
Net income growth 3Y	47.13%
Net income growth 5Y	-3.53%
Net income growth years	0
OCF growth	23.7%
OCF growth (Q)	100.14%
OCF growth (QoQ)	1.42%
OCF growth 3Y	2.67%
OCF growth 5Y	6.9%
Operating income growth	-16.95%
Operating income growth (Q)	-40.78%
Operating income growth 3Y	13.81%
Operating income growth 5Y	-3.59%
Revenue growth	10.01%
Revenue growth (Q)	16.5%
Revenue growth (QoQ)	6.91%
Revenue growth 3Y	2.41%
Revenue growth 5Y	2.53%
Revenue growth quarters	6
Revenue growth years	1

Financial statements

Income-statement and cash-flow amounts, totals and per share.

Metric	Value
Depreciation and amortization	$4.9M
EBIT	$1.6B
EBITDA	$1.6B
EPS	$1.86
FCF per share	$5.18
Financing cash flow	$-282.7M
Free cash flow	$3B
Free cash flow minus SBC	$2.5B
Gross profit	$2.4B
Investing cash flow	$-2.5B
Net borrowing	$954.5M
Net cash flow	$180.1M
Net income	$812M
Operating cash flow minus SBC	$2.5B
Operating income	$1.6B
Revenue	$2.5B
Stock-based compensation	$427.7M

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Altman Z-Score	1.73
Book value per share	$15.33
Debt / EBITDA	5.75
Debt / equity	0.92
Debt / FCF	3.01
Goodwill	$923.5M
Interest coverage	4.3
Long-term assets	$18.1B
Long-term liabilities	$9.4B
Net cash (debt)	$-8.1B
Net cash / market cap	-21.81%
Net debt / EBITDA	5.22
Net debt / equity	0.83
Net debt / FCF	2.73
Piotroski F-Score	6
Shareholders' equity	$9.8B
Tangible book value	$5.9B
Tangible book value per share	$13.26
Total assets	$19.8B
Total cash	$837M
Total debt	$9B
Total liabilities	$10B
WACC	5.87%

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Asset turnover	0.13
Current assets	$1.8B
Current liabilities	$630.9M
Current ratio	2.8
Net working capital	$676.7M
Quick ratio	2.79
Working capital	$1.1B
Working capital turnover	3.5

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback yield / dilution	3.88%
Dividend growth	6.82%
Dividend growth (3Y)	5.52%
Dividend growth (5Y)	6.69%
Dividend growth years	5
Dividend payment date	2026-12-10
Dividend payment years	7
Dividend payout frequency	Quarterly
Dividend per share	$0.94
Dividend yield	1.46%
Ex-dividend date	2026-11-13
FCF payout ratio	18.16%
Last dividend	$0.24
Payout ratio	50.42%
Shareholder yield	5.34%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
150-day SMA	$55.93
1D price change	-0.74%
1M price change	10.6%
1M total return	10.6%
1W price change	3.42%
1W total return	3.42%
1Y price change	72.79%
1Y return CAGR	76.21%
1Y total return	76.14%
20-day SMA	$59.92
200-day SMA	$52.96
3M price change	9.62%
3M total return	10.06%
3Y price change	145.63%
3Y return CAGR	38.4%
3Y total return	165.18%
50-day SMA	$60.05
50-day SMA vs 200-day SMA	50over200
52-week high	$65.51
52-week high date	2026-10-27
52-week low	$35.92
52-week low date	2025-10-28
5Y price change	74.9%
5Y return CAGR	14.48%
5Y total return	96.58%
6M price change	29.67%
6M total return	30.77%
All-time high	$65.51
All-time high date	2026-10-27
All-time low	$24.05
All-time low date	2024-12-19
Average true range (ATR)	$1.39
Average volume	3.1M
Beta (1Y)	-0.01
Beta (2Y)	0.13
Beta (5Y)	0.41
Change from 52-week high	-1.08%
Change from 52-week low	80.43%
Change from all-time high	-1.72%
Change from all-time low	167.69%
Change from open	1.6%
Day's gap	-2.3%
Dollar volume	$125.9M
High price	$65.23
Low price	$63.50
Monthly RSI	79.91
Open price	$63.78
Position in 52-week range	75.14%
Premarket change	-2.28%
Premarket close	$65.28
Premarket price	$63.79
Premarket volume	25.7K
Previous close	$65.28
Price vs 150-day SMA	15.12%
Price vs 20-day SMA	7.44%
Price vs 200-day SMA	21.57%
Price vs 50-day SMA	7.21%
Relative volume	0.62
Return from IPO open	47.27%
Return from IPO price	131.43%
RSI	68.02
Sharpe ratio	2.35
Sharpe ratio (3Y)	1.26
Sharpe ratio (5Y)	0.51
Sortino ratio	4.06
Sortino ratio (3Y)	2.28
Sortino ratio (5Y)	1.02
Volume	1.9M
Weekly RSI	70.29
YTD price change	66.62%
YTD total return	68.91%

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	417.6M
Float percentage	72.62%
Shares change (QoQ)	0.01%
Shares change (YoY)	-3.88%
Shares held by insiders	6.1%
Shares held by institutions	85.03%
Shares outstanding	575M
Short % of float	3.09%
Short % of shares	2.24%
Short ratio	3.9 days

Deeper analysis on RPRX

14 sections in the full report · jump straight to what you need

Forecast

Base and Bull forecast paths with report-date return framing.

→

Valuation

Fair-value bridge, DCF, owner earnings, and peer multiples.

→

Sensitivity

Cost-of-equity and terminal-growth stress table.

→

Risks

Kill scenarios, soft-pass flags, and downside catalysts.

→

Earnings

Next earnings setup and beat / inline / miss thresholds.

→

Position sizing

Entry, exit, conviction, and quarterly monitoring rules.

→

Financials

Revenue, margins, cash flow, and balance-sheet context.

→

Peers

Relative valuation and profitability against the cohort.

→

Moat

Economic-profit evidence and competitive advantage risk.

→

Industry cycle

Sector phase, capital cycle, and secular tailwinds.

→

Frequently asked questions

About this RPRX report

Is a complete RPRX research report available?

No complete published report is available for Royalty Pharma plc (RPRX) on this page. Market-directory data, when present, is not a substitute for a validated stock analysis.

Royalty Pharma plc (RPRX)

Price

Financial snapshot

Fair-value bridge

Latest news · RPRX

Valuation

Profitability

Balance sheet

Trading

Next earnings

Sector percentile context

All RPRX indicators

Profile and market data

Valuation

Profitability

Growth

Financial statements

Financial strength

Liquidity

Dividends and buybacks

Performance and technicals

Ownership and float

Deeper analysis on RPRX

Frequently asked questions